Lyophilization CONTRACT MANUFACTURING Lyophilization: Sustained growth in all directions L’Europe apparaît comme cytotoxiques injectables un terrain très attractif pour lesquels les capaci- pou rles sous-traitants tés de lyophilisation dis- œuvrant dans la lyohip- ponibles en sous-traitance lisation. Suite àl’arêtr seront très réduites de d’activité du plus i r-mpo2019 à 2022. tant sous-traitatnpharma- Déjà bien installé en ceutique américain ans ad l Europe, Elaïapharm lyophilisation, Ben Vnu,ee(groupe danois Lundbeck) lademande de sou-trisa- remarque qu’il est de tance en lyophilisation plus en plus consulté y serait mêmebeauopcu pour cette technologie plus forte que l fre.’of Ce depuis quelques quenuance Rcpei harm années, notamment pour à la lueur des éudest de lyophiliser des adjuvants PharmSource . L’impatc de médicaments et de de arrêtcet s eevrra traceurs pour imagerie. surtout sur les proudits Avara Pharmaceuticals 111 contract manufacturer, that over the past years, of injectable products. laboratories as well, Ben Venue, the demand they have been more and Last year, it acquired since the management for contract manufacturing more approached for this from Hospira an Italian estimates that “there is a lyophilization services technology, particularly production site for sterile crucial lack of high-quality is bound to surpass the for the lyophilization of medicines, also specialized lyophilization capacity”. offer. A trend confirmed bypharmaceutical adjuvants in lyophilization. Specialised in clinical Recipharm, as well, based and imaging tracers. Avara batches, it has cumulated on PharmSource studies. Pharmaceutical Services Other undoubtedly less extensive experience in The impact of this cessationis another CDMO which competitive CMDOs have orphan medicines, as well will be particularly will eventually play a also made their entry in as in complex formulation visible with cytotoxic significant part in the this area. The American products. Established 5 injectable products, for European lyophilization CMO LSNE (established in years ago, the German which the available market. Operating all over 1997), which nevertheless company LYOcontract contract manufacturing the world, it continues to remains a discrete presence states that they are lyophilization capacity willexpand its footprint. It hasand operates only for already present on the be reduced between 2019 recently purchased from US-based production sites. “biotech” markets (least and 2022. Novartis a production site Still, as not long ago it active molecules) and those based in Quebec for sterile became the property of a for conventional products. Already well established inlyophilised products, the European private equity Europe, Elaïapharm (Danish most important Canadian investment fund, it is tryingVials and bulk, two Group Lundbeck) points out site for the production to seduce the European powerful dynamics The Healthcare Packaging Products Magazine /Doses 722018 - September